

For Release Time

30th of May 2018

MedCom Announces Availability of BiopSee® in the USA

The Successful fusion MRI/US BiopSee® system received FDA approval

Darmstadt, Germany— 30th of May 2018 — MedCom announced immediate availability of BiopSee®, enabling urologists to benefit from the advantages of the fusion functionalities of BiopSee® for their transperineal and transrectal prostate biopsies.

“BiopSee® 3 has received FDA approval and is now available for use in the United States. We are looking forward to expanding our business in the USA where prostate cancer is the most commonly diagnosed non-skin cancer and the second leading cause of cancer death” said Prof. Dr. Georgios Sakas, CEO at MedCom.

Early prostate cancer diagnosis means treatment is possible

Many patients in Europe have been benefited from the precise diagnosis through BiopSee® and had an early prostate treatment, saving potential lives and now this advanced technology is available for the US citizens.

“Simply gives you the best prostate biopsy in the world: This system allows for exceptionally precise biopsies in a very easy way. In addition to integrating MRI data, it captures every sample location in all 3 dimensions. Thus we can attribute to each biopsy sample and/or positive finding its aggressiveness and exact location.” said Prof. Dr. Hadaschik, Director of the Urologist Clinic of the University Hospital Essen in Germany

BiopSee® Availability

MedCom’s commitment to always deliver state-of-the-art solutions for patients’ diagnosis and treatment introduced BiopSee® in the European Market in 2012, establishing the product as one of the preferred fusion systems for University Clinics and key opinion leaders, as well as for small private clinics looking for the best diagnosis for their patients.

About MedCom

MedCom was founded in 1997 and is specialized in the field of medical imaging. MedCom offers innovative and advanced imaging-based products with emphasis on interventional/surgical navigation and cancer treatment solutions (instrument navigation, brachytherapy, patient positioning & verification, virtual simulation). MedCom developed the first commercially released “fusion imaging” with integrated intervention planning product for liver (2002) and prostate (2007). As an OEM/B2B company, MedCom is providing products for various global corporations offering integrated clinical solutions,

as well as to high-end clinics in the research sector. For more information about MedCom GmbH, please visit www.medcom-online.de

BiopSee® is a registered trademark of MedCom in the United States

The names of actual companies and products mentioned herein may be the trademarks of their respective owners.

For more information

+49 6151 951 47 0

biopsee@medcom-online.de

<http://www.biopsee.de>